Current Report Filing (8-k)
March 09 2017 - 04:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 9, 2017
Flexion Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36287
|
|
26-1388364
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
10 Mall Road, Suite 301
Burlington, Massachusetts
|
|
01803
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (781) 305-7777
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On March 9, 2017, Flexion
Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2016. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this Item 2.02 and Exhibit 99.1 hereto is being furnished and shall not be deemed filed for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the
Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On March 9, 2017, Frederick W. Driscoll, Chief Financial Officer of Flexion Therapeutics, Inc., informed the Company that he will retire
effective March 31, 2017, due to a personal family matter. Mr. Driscoll has committed to remain with the Company in a consulting capacity after March 31, 2017, until the Company concludes its search for a new Chief Financial Officer
and to help with that persons transition into the role.
Forward-Looking Statements
Certain statements in this report that are not historical facts are forward-looking statements that involve a number of risks and
uncertainties. Such forward-looking statements include statements relating to Mr. Driscolls planned retirement and the timing and process for the transition of the Companys Chief Financial Officer position. These statements are only
predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those stated in any such statements due to various factors, some of which are discussed in
the Companys annual report on Form 10-K for the year ended December 31, 2016 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary
statement and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof.
Item 9.01
|
Financial Statements and Exhibits.
|
|
|
|
|
|
Exhibit No.
|
|
|
Description
|
|
|
|
99.1
|
|
|
Press Release of Flexion Therapeutics, Inc. dated March 9, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Flexion Therapeutics, Inc.
|
|
|
|
|
Dated: March 9, 2017
|
|
|
|
By:
|
|
/s/ Frederick W. Driscoll
|
|
|
|
|
|
|
Frederick W. Driscoll
|
|
|
|
|
|
|
Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
|
|
Exhibit No.
|
|
|
Description
|
|
|
|
99.1
|
|
|
Press Release of Flexion Therapeutics, Inc. dated March 9, 2017.
|
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Mar 2023 to Mar 2024